Besoin d’Aide pour Analyser et Interpréter Vos Données ?
AltraBio est une entreprise de recherche sous contrat de confiance, spécialisée dans l’analyse de données biologiques et médicales. Nous vous aidons à libérer tout le potentiel de vos données de cytométrie, omique et médicales. En utilisant des méthodes statistiques avancées et l’intelligence artificielle, nous fournissons des insights qui stimulent l’innovation et la prise de décision.
Nous sommes partenaire de recherche et développement d’entreprises leaders et d’hôpitaux universitaires dans divers secteurs, y compris les produits pharmaceutiques, les dispositifs médicaux, le diagnostic et les dermo-cosmétiques.
Apprenez-en plus sur nos services :
Financement
Témoignages
« Top of the field »
« They are highly efficient and agile; you won’t interact with much people, so they are quick to respond and provide high-quality service »
« If there is some problem, or troubleshooting is necessary, or some change in the workflow, they are very flexible.»
« Exceptional »
« We really appreciate AltraBio because they provide one-stop full service, so we don’t need to worry about a lot of former problems, and also quality of results »
« Supervised approach is really a mature approach, I think there is an absolute need for having this solution… »
« The quality of the results we got from AB was quite remarkable in the good »
« AltraBio is viewed as automating subject matter experts, with the ability to do the same work. It allows us to free up subject matter experts at scale so a subject matter expert doesn’t have to spend as much time doing gating or reviewing gatings, and it all hinges on the quality that they provide. So for us, that’s the biggest selling point; the quality allow us to be able to say, OK this technology is almost as good as subject matter experts in this domain, and the pricing and the speed make it such that it becomes a feasible solution for us to say we can free up the scientists to do other things and this part can be handled by AltraBio. »
« Automated gating is there… In 2018, when automated gating was discussed at CYTO, some people stood up and said: « No! This is not going to work. Gating has been done by scientists & experts, and you can’t just put a computer to do their job. » We know now that it is not true because the Altrabio’s solutions are now doing it. It is pretty amazing. »
« This is accurate; we can use it at scale, so we don’t have to do the manual gating. »
« They do that extra bit of QC on their hand; they also check the transfers and put that extra effort in to make sure that what we do is accurate »
« The work we do with AltraBio is a partnership. I’ll make an example of the last analysis that we did; there were some timelines that needed to be met and they stepped in and said « OK we‘ll get this done in a few days », not in a week, not in a month … When you have that relationship, when you understand the value and you understand the timelines of the customer, that felt really like a partnership and I think we’re heading in that direction… »
« They do cutting-edge work, we clearly like the innovation part »
« In clinical trials, we could get thousands of samples for different panels… The scale is clearly so big, not many companies can do this kind of work in production mode, on the labor scale »
« They fit clients’ need. »
« Even in the age of generative AI, Altrabio’s two decades of expertise in maths, stats, biology, and medical science remain invaluable. They don’t just talk, they do. No flashy marketing, no inflated costs, just solid, thoughtful work from study design to actionable insights. A trusted partner, for twenty years, in a world full of noise. Highly recommend working with them to make real sense of your complex biomedical and omics data. »
Dernières Publications
2025
Identifying potential novel widespread determinants of bacterial pathogenicity using phylogenetic-based orthology analysis Article de journal
Dans: Front. Microbiol., vol. 16, 2025, ISSN: 1664-302X.
Boosting effect of high-dose influenza vaccination on innate immunity among elderly: a randomized-control trial Article de journal
Dans: JCI Insight, 2025, ISSN: 2379-3708.
2024
BacSPaD: A Robust Bacterial Strains' Pathogenicity Resource Based on Integrated and Curated Genomic Metadata Article de journal
Dans: Pathogens, vol. 13, no. 8, 2024, ISSN: 2076-0817.